Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37983491)
Watch
English
Current status of immunological approaches for the treatment of prostate cancer
scientific article published on May 2012
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
title
Current status of immunological approaches for the treatment of prostate cancer
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
main subject
immunology
1 reference
based on heuristic
inferred from title
prostate cancer
1 reference
based on heuristic
inferred from title
author
Emmanuel S Antonarakis
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
author name string
Charles G Drake
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
language of work or name
English
1 reference
based on heuristic
inferred from title
publication date
1 May 2012
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
published in
Current Opinion in Urology
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
volume
22
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
issue
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
page(s)
197-202
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
cites work
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Abiraterone and increased survival in metastatic prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Prostate cancer as a model for tumour immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
DNA vaccines for the treatment of prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Monoclonal antibodies: versatile platforms for cancer immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
The anticancer immune response: indispensable for therapeutic success?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Immunotherapy via dendritic cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
6 September 2017
Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
23 June 2018
Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3444809
retrieved
1 September 2018
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/22328018
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/22328018
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1097/MOU.0B013E3283519AD5
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
PMC publication ID
3444809
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
PubMed publication ID
22328018
1 reference
stated in
Europe PubMed Central
PMC publication ID
3444809
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22328018%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
ResearchGate publication ID
221826366
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit